Table 14.
Selection of drugs for management of associated comorbidities in obesity[53]
| Comorbidities | Drugs that can potentially lead to weight gain (to be avoided) | Drugs that are weight neutral or weight reducing (to be used) |
|---|---|---|
| Diabetes | Sulfonylureas, piogltazone, insulin | SGLT2 inhibitors, GLP1 RA, metformin, |
| DPP4i | ||
| Hypertension | Betablockers (Metoprolol | ACEIs, ARBs, calcium channel blockers, diuretics |
| Atenolol | ||
| Propranolol | ||
| Antidepressants | SSRIs (sertraline, citalopram, escitalopram, fluoxetine) | Desvenlafaxine |
| Bupropion | ||
| MAOIs (e.g., phenelzine) | Venlafaxine | |
| TCAs (e.g., amitriptyline, clomipramine, doxepin, imipramine, nortriptyline, protriptyline) | ||
| Drugs used for neuropathy and anti-epileptic drugs | Gabapentin | Topiramate |
| Pregabalin | Lamotrigine | |
| Carbamazepine | Zonisamide | |
| Divalproex | ||
| Lithium | ||
| Valproic acid | ||
| Vigabatrin | ||
| Anti-psychotics | Quetiapine | Aripiprazole |
| Clozapine | Haloperidol | |
| Olanzapine | Ziprasidone | |
| Risperidone | ||
| Thioridazine | ||
| Rheumatologic disorders | Prednisone | Alternatives for rheumatologic disorders: |
| Hydrocortisone | NSAIDs | |
| Methyl-prednisolone | Biologics/DMARDs | |
| Nontraditional therapies | ||
| Hormonal agents | Progestins (e.g., medroxyprogesterone or megestrol acetate) | For contraception, consider alternative methods (e.g., barrier methods, copper IUD) |